Filtern
Erscheinungsjahr
- 2017 (3) (entfernen)
Dokumenttyp
Sprache
- Englisch (3)
Schlagworte
- ADC (1)
- Antibody (1)
- Antibody drug conjugate (1)
- Bioconjugate (1)
- Carrier load (1)
- Carrier protein (1)
- Click chemistry (1)
- Click reaction (1)
- Conjugation density (1)
- Conjugation ratio (1)
The conventional hybridoma screening and subcloning process is generally considered to be one of the most critical steps in hapten-specific antibody production. It is time-consuming, monoclonality is not guaranteed, and the number of clones that can be screened is limited. Our approach employs a novel hapten-specific labeling technique of hybridoma cells. This allows for fluorescence-activated cell sorting (FACS) and single-cell deposition and thereby eliminates the above-mentioned problems. A two-step staining approach is used to detect antigen specificity and antibody expression: in order to detect antigen specificity, hybridoma cells are incubated with a hapten−horseradish peroxidase conjugate (hapten−HRP), which is subsequently incubated with a fluorophore-labeled polyclonal anti-peroxidase antibody (anti-HRP−Alexa Fluor 488). To characterize the expression of membrane-bound immunoglobulin G (IgG), a fluorophore-labeled anti-mouse IgG antibody (anti-IgG−Alexa Fluor 647) is used. Hundreds of labeled hybridoma cells producing monoclonal antibodies (mAbs) specific for a hapten were rapidly isolated and deposited from a fusion mixture as single-cell clones via FACS. Enzyme-linked immunosorbent assay (ELISA) measurements of the supernatants of the sorted hybridoma clones revealed that all hapten-specific hybridoma clones secrete antibodies against the target. There are significant improvements using this high-throughput technique for the generation of mAbs including increased yield of antibody-producing hybridoma clones, ensured monoclonality of sorted cells, and reduced development times.
Predictable Peptide Conjugation Ratios by Activation of Proteins with Succinimidyl Iodoacetate (SIA)
(2017)
The small heterobifunctional linker succinimidyl iodoacetate (SIA) was examined for the preparation of peptide–protein bioconjugates with predicable conjugation ratios. For many conjugation protocols, the protein is either treated with a reductant to cleave disulfide bonds or is reacted with thiolation chemicals, such as Traut’s reagent. Both approaches are difficult to control, need individual optimization and often lead to unsatisfactory results. In another popular approach, a heterobifunctional linker with a N-hydroxysuccinimide (NHS) and a maleimide functionality is applied to the protein. After the activation of some lysine ε-amino groups with the NHS ester functionality, a cysteine-containing peptide is attached to the activated carrier protein via maleimide. Particularly, the maleimide reaction leads to some unwanted byproducts or even cleavage of the linker. Many protocols end up with conjugates with unpredictable and irreproducible conjugation ratios. In addition, the maleimide-thiol addition product should be assumed immunogenic in vivo. To avoid these and other disadvantages of the maleimide approach, we examined the known linker succinimidyl iodoacetate (SIA) in more detail and developed two protocols, which lead to peptide–protein conjugates with predefined average conjugation ratios. This holds potential to eliminate tedious and expensive optimization steps for the synthesis of a bioconjugate of optimal composition.
A method for the examination of the epitope of a monoclonal antibody against a peptide related to hepcidin-25, known as a biomarker in the ion metabolism, was developed. Characterizing the exact binding site helps to understand the properties of the antibody. A peptide consists of different amino acids, each contributing differently to the binding strength. To examine the influence of the amino acids, each amino acid was subsequently exchanged by glycine. If the respective amino acid is critical for binding to the antibody, a significant drop in the binding affinity should be observed.
The epitope screening of monoclonal antibodies is a complex and elaborate procedure. For this approach, variants of the peptides were synthesized by conventional Fmoc-based peptide synthesis. The solid support was chosen to be suitable for the synthesis and additional screening against the antibody. To determine the binding affinity, the bead-bound peptides were incubated with a fluorophore-labeled antibody. After the incubation, the beads were placed on a slide and the fluorescence was detected by a fluorescence scanner. A high fluorescence indicates a high binding affinity and vice versa.